ArticleTranslational oncology2026
TMC7 promotes colorectal cancer metastasis via inhibition of PKN2 and regulation of hypoxia-adaptive responses.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis is the leading cause of mortality in colorectal cancer (CRC). The hypoxic tumor microenvironment contributes to CRC progression by activating hypoxia-adaptive responses and the Warburg effect. This study investigates the role of transmembrane channel-like protein 7 (TMC7) in CRC metastasis. TMC7 is significantly upregulated in CRC tissues in patients, particularly in metastatic lesions. High TMC7 expression was associated with reduced survival and a higher incidence of metachronous liver metastases. Moreover, TMC7-high tumors exhibited enhanced glucose uptake. In vitro, TMC7 promoted CRC cell proliferation and invasion under hypoxic conditions, accompanied by HIF-1α nuclear translocation and activation of hypoxia-adaptive responses. In vivo, TMC7 significantly accelerated lung metastasis and shortened overall survival in a nude mouse xenograft model. Mechanistically, protein kinase N2 (PKN2) acts as a negative regulator of HIF1α activity, suppressing hypoxia adaptation and glycolysis. TMC7 inhibited PKN2 activity, thereby relieving its repression on HIF1α and facilitating HIF1α nuclear accumulation. This cascade ultimately enhances glycolytic flux and supports metastatic progression. Importantly, ectopic expression of PKN2 reversed the pro-metastatic and metabolic reprogramming phenotypes induced by TMC7. Furthermore, elevated TMC7 predicted inferior outcomes following chemotherapy and immunotherapy. Together, these findings uncover a novel TMC7-PKN2-HIF1α signaling axis that drives CRC metastasis through regulation of hypoxia adaptation and the Warburg effect. This study provides new mechanistic insights into CRC metastasis and highlights TMC7 as a potential therapeutic target for precision treatment of metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.